Abstract
The effects of a newly developed pyridone carboxylic acid antibacterial agent, pazufloxacin (PZFX), were investigated in six healthy male volunteers. PZFX was given orally in three doses of 300mg each for 7 days.
PZFX did not decrease the level of total bacterial counts in feces. The impact was more marked on aerobic and facultative aerobic components than anaerobic components. PZFX caused a decrease in Megasphaera, Veillonella, Fusobacterium and Clostridium perfringens, but not in Bacteroides fragilis group organisms. Members of the family Enterobacteriaceae decreased markedly during treatment and returned to normal within 1 week after cessation of administration.
Clostridium difficile was recovered sporadically before, during and after administration of PZFX.
